ADIL
ADIAL PHARMACEUTICALS, INC.
Next earnings Aug 11, 2026 · consensus $-0.84 EPS
Last earnings +0.7% on 2026-05-11
$2.56
▼ -0.78%$2.56▼ -61.06%
over 1Y
L $1.36EODHDH $15.75
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.8%
1W-5.5%
1M+7.1%
3M+56.1%
YTD-57.2%
1Y-61.1%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Conservative balance sheet (liabilities/equity 0.26x).
Return on equity -151.2% · latest
ADIAL PHARMACEUTICALS, INC. shows limited reported revenue, and -151.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$19.3M | -$10.9M | -$6.89M | -$8.28M | -$7.80M |
| Net income | -$19.4M | -$12.7M | -$5.12M | -$13.2M | -$7.98M |
| Diluted EPS | -$1.04 | -$12.71 | -$3.60 | -$68.01 | -$11.93 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$2.23M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-218.2%
FCF yield-179.4%
Quality & risk
ROIC (est.)-116.8%
Free cash flow-$6.56M
Total debt—
Net cash$5.88M
Piotroski F-Score4/6
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY-78.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗SCHEDULE 13GFiling2026-06-24open ↗4Period ending 2026-06-112026-06-16open ↗3Period ending 2026-06-112026-06-16open ↗4Period ending 2026-06-122026-06-16open ↗3Period ending 2026-06-112026-06-16open ↗8-KPeriod ending 2026-06-112026-06-11open ↗SCHEDULE 13G/AFiling2026-05-15open ↗8-KPeriod ending 2026-05-112026-05-11open ↗10-QPeriod ending 2026-03-312026-05-08open ↗4Period ending 2026-04-072026-04-09open ↗4Period ending 2026-04-072026-04-09open ↗8-KPeriod ending 2026-04-072026-04-09open ↗
Frequently asked
- Is ADIAL PHARMACEUTICALS, INC. (ADIL) a buy?
- ADIL currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.26x).
- What is ADIAL PHARMACEUTICALS, INC.'s quality score?
- ADIL scores 59.87179487179487/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001513525, latest 10-Q filed 2026-05-08) · EODHD · as of 6/26/2026, 7:52:28 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.